

Amendments to the Claims

Claim 1 (Currently amended) An extended release pharmaceutical composition in the form of a capsule comprising:

a powder blend of phenytoin sodium; and one or more hydrophilic polymers,
wherein the powder blend has been screened through a mesh after blending but before filling in the capsules;

wherein the hydrophilic polymers comprise a combination of a cellulose ether and carbohydrate gum.

Claims 2-5 (Cancelled)

Claim 6 (Original) The composition according to claim 1, wherein the composition comprises from about 40 percent to about 70 percent by weight of phenytoin sodium.

Claim 7 (Original) The composition according to claim 1, wherein the composition comprises from about 10 percent to about 30 percent by weight of the one or more hydrophilic polymers.

Claim 8 (Cancelled)

Claim 9 (Previously presented) The composition according to claim 1, wherein the carbohydrate gum comprises one or more of xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan gum, locust bean gum, and mixtures thereof.

Claim 10 (Original) The composition according to claim 9, wherein the carbohydrate gum comprises xanthan gum.

Claim 11 (Previously presented) The composition according to claim 1, wherein the cellulose ether comprises one or more of methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxypropyl butyl cellulose, carboxymethyl cellulose, and combinations thereof.

Claim 12 (Original) The composition according to claim 11, wherein the cellulose ether comprises hydroxypropyl cellulose.

Claim 13 (Original) The composition according to claim 11, wherein the cellulose ether comprises hydroxypropyl methylcellulose.

Claims 14-15 (Cancelled)

Claim 16 (Previously presented) The composition according to claim 1, wherein the cellulose ether comprises a combination of hydroxypropyl cellulose and hydroxypropyl methylcellulose and the carbohydrate gum comprises xanthan gum.

Claim 17 (Original) The composition according to claim 1, further comprising one or more pharmaceutically acceptable excipients.

Claim 18 (Original) The composition according to claim 17, wherein the one or more pharmaceutically acceptable excipients comprise one or more of diluents, lubricants and glidants.

Claim 19 (Original) The composition according to claim 18, wherein the diluents comprise one or more of microcrystalline cellulose, powdered cellulose, lactose, starch, mannitol, calcium hydrogen phosphate, and dextrose.

Claim 20 (Original) The composition according to claim 19, wherein the diluent comprises microcrystalline cellulose.

Claim 21 (Original) The composition according to claim 18, wherein the lubricant comprises one or more of talc, magnesium stearate, calcium stearate, stearic acid, hydrogenated vegetable oil, polyethylene glycol, sodium stearyl fumarate and sodium benzoate.

Claim 22 (Original) The composition according to claim 21, wherein the lubricant comprises magnesium stearate.

Claim 23 (Original) The composition according to claim 21, wherein the lubricant comprises talc.

- Claim 24 (Original) The composition according to claim 18, wherein the glidant comprises one or more of colloidal silicon dioxide and talc.
- Claim 25 (Original) The composition according to claim 24, wherein the glidant comprises colloidal silicon dioxide.
- Claim 26 (Original) The composition according to claim 1, wherein the composition has the following in vitro dissolution profile when tested using USP Apparatus I in water at 75 rpm:
- a) not more than about 35 percent released in about 30 minutes,
 - b) between about 30 percent and about 75 percent released in about 60 minutes, and
 - c) not less than about 65 percent released in about 120 minutes.
- Claim 27 (Currently amended) A process for preparing an extended release pharmaceutical composition comprising a blend of phenytoin sodium and one or more hydrophilic polymers; the process comprising:
- a) blending phenytoin sodium and one or more hydrophilic polymers, wherein the hydrophilic polymers comprise a combination of a cellulose ether and carbohydrate gum,
 - b) screening the blend through a mesh, and
 - c) filling the blend into capsules.
- Claims 28-44 (Cancelled)
- Claim 45 (Currently amended) A method for controlling or treating one or more of generalized tonic-clonic (grand mal) seizures and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery in a patient in need thereof, the method comprising administering an extended-release pharmaceutical composition comprising:

a powder blend of phenytoin sodium and one or more hydrophilic polymers,
wherein the hydrophilic polymers comprise a combination of a cellulose ether
and carbohydrate gum and the powder blend has been screened through a
mesh after blending but before filling in the capsules;

wherein the hydrophilic polymers comprise a combination of a cellulose ether
and carbohydrate gum.

Claim 46 (Original) The method according to claim 45, further comprising
administering an additional pharmaceutically active agent.

Claims 47-48 (Cancelled)

Claim 49 (Previously presented) The composition according to claim 1, wherein the
powder blend forms a matrix after contacting an aqueous media and the
matrix retains at least about 20% of the phenytoin after 1 hour.

Claim 50 (Previously presented) The composition according to claim 49, wherein the
matrix retains at least about 30% of the phenytoin after 1 hour.

Claim 51 (Previously presented) The composition according to claim 49, wherein the
matrix retains at least about 60% of the phenytoin after 1 hour.